Seeding of vascular grafts with genetically modified endothelial cells: Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo

Circulation

Volumn 93, Issue 7, 1996, Pages 1439-1446

  Dunn, Peter F ^a   Newman, Kurt D ^a,b   Jones, Michael ^a   Yamada, Izumi ^a   Shayani, Vafa ^a   Virmani, Renu ^c   Dichek, David A ^a,d  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

Author keywords

carotid arteries; cells; plasminogen activators; viruses

Indexed keywords

PLASMINOGEN ACTIVATOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL GRAFT; BLOOD VESSEL PROSTHESIS; CAROTID ARTERY; CORONARY ARTERY BYPASS GRAFT; FEMORAL ARTERY; GENETIC ENGINEERING; GRAFT REJECTION; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; VASCULAR ENDOTHELIUM;

EID: 0029920491     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.7.1439     Document Type: Article

References (52)

1. Darling RC, Linton RR. Durability of femoropopliteal reconstructions. Am J Surg. 1972;123:472-479.
2. Rutherford RB, Nishikimi N. Graft thrombosis and thromboembolic complications. In: Rutherford RB, ed. Vascular Surgery. Philadelphia. Pa: WB Saunders Co; 1989:501-510.
3. Eickhoff JH, Broome A, Ericsson BF, Hansen HJB, Kordt KF, Mouritzen C, Kvernebo K, Norgren L, Rostad H, Trippestad A. Four years' results of a prospective, randomized clinical trial comparing polytetrafluoroethylene and modified human umbilical vein for below-knee femoropopliteal bypass. J Vasc Surg. 1987;6:506-511.
4. Sapsford RN, Oakley GD, Talbot S. Early and late patency of expanded polytetrafluoroethylene vascular grafts in aorta-coronary bypass. J Thorac Cardiovasc Surg. 1981;81:860-864.
5. Herring MB, Gardener A, Glover J. A single-staged technique for seeding vascular grafts with autogenous endothelium. Surgery. 1978; 84:498-504.
6. Sharefkin JB, Latker C, Smith M, Cruess D, Clagett GP, Rich NM. Early normalization of platelet survival by endothelial cell seeding of Dacron arterial prostheses in dogs. Surgery. 1982;92:385-393.
7. Stanley JC, Burkel WE, Ford JW, Vinter DW, Kahn RH, Whitehouse WM Jr, Graham LM. Enhanced patency of small diameter externally supported Dacron iliofemoral grafts seeded with endothelial cells. Surgery. 1982;92:994-1005.
8. Zilla P, Deutsch M, Meinhart J, Puschmann R, Eberl T, Minar E, Dudczak R, Lugmaier H, Schmidt P, Noszian I, Fischlein T. Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J Vasc Surg. 1994;19:540-548.
9. Newman KD, Nguyen N, Dichek DA. Quantification of vascular graft seeding by use of computer-assisted image analysis and genetically modified endothelial cells. J Vasc Surg. 1991;14:140-146.
10. Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC. Implantation of vascular grafts lined with genetically modified endothelial cells. Science. 1989;244:1344-1346.
11. Podrazik R, Whitehill TA, Ekhterae D, Williams WD, Messina LM, Stanley JC. High-level expression of recombinant human t-PA in cultivated canine endothelial cells under varying conditions of retroviral gene transfer. Ann Surg. 1992;216:446-453.
12. Sackman JE, Freeman MB, Petersen MG, Alleban Z, Niemeyer GP, Lothrop CD. Synthetic vascular grafts seeded with genetically modified endothelium in the dog: evaluation of the effect of seeding technique and retroviral vector on cell persistence in vivo. Cell Transplant. 1995;4:219-235.
13. Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF. Seeding of intravascular stents with genetically engi-neered endothelial cells. Circulation. 1989;80:1347-1353.
14. Dichek DA, Nussbaum O, Degen SJF, Anderson WF. Enhancement of the fibrinolytic activity of sheep endothelial cells by retroviral vector-mediated gene transfer. Blood. 1991;77:533-541.
15. Shayani V, Newman KD, Dichek DA. Optimization of recombinant t-PA secretion from seeded vascular grafts. J Surg Res. 1994;57: 495-504.
16. Dichek DA, Lee SW, Nguyen NH. Characterization of recombinant plasminogen activator production by primate endothelial cells transduced with retroviral vectors. Blood. 1994;84:504-516.
17. Flugelman MY, Jaklitsch MT, Newman KD, Casscells W, Bratthauer GL, Dichek DA. Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation. 1992;85:1110-1117.
18. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1991;7:980-990.
19. Bassin RH, Tuttle N, Fischinger PJ. Rapid cell culture assay technique for murine leukaemia viruses. Nature. 1971;229:564-566.
20. Ferry N, Duplessis O, Houssin D, Danos O, Heard J-M. Retroviral-mediated gene transfer into hepatocytes in vivo. Proc Natl Acad Sci U S A. 1991;88:8377-8381.
21. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res. 1993;73:797-807.
22. Anderson JS, Price TM, Hanson SR, Harker LA. In vitro endothelialization of small-caliber vascular grafts. Surgery. 1987;101:577-586.
23. Morgan RA, Cornetta K, Anderson WF. Applications of the polymerase chain reaction in retroviral vector-mediated gene transfer and the analysis of gene-marked TIL cells. Hum Gene Ther. 1990;1: 135-149.
24. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Press; 1989.
25. Glantz SA. Primer of Biostatistics. New York, NY: McGraw-Hill Publishing Co; 1987.
26. Dichek DA. Quertermous T. Variability in messenger RNA levels in human umbilical vein endothelial cells of different lineage and time in culture. In Vitro Cell Dev Biol. 1989;25:289-292.
27. Rodamski JS, Jarrell BE, Williams SK, Koolpe EA, Greener DA, Carabassi RA. Initial adherence of human capillary endothelial cells to Dacron. J Surg Res. 1987;42:133-140.
28. Rosenman JE, Kempczinski RF, Pearce WH, Silberstein EB. Kinetics of endothelial cell seeding. J Vasc Surg. 1985;2:778-784.
29. Diamond SL, Eskin SG, McIntire LV. Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. Science. 1989;243:1483-1485.
30. Mosquera DA, Goldman M. Endothelial cell seeding. Br J Surg. 1991;78:656-660.
31. Welch M, Durrans D, Carr HMH, Vohra R, Rooney OB, Walker MG. Endothelial cell seeding: a review. Ann Vasc Surg. 1992;6: 473-479.
32. Nachman RL, Hajjar KA. Endothelial cell fibrinolytic assembly. Ann N Y Acad Sci. 1991;614:240-249.
33. Loscalzo J, Braunwald E. Tissue plasminogen activator. N Engl J Med. 1988;319:925-931.
34. Stanley JC. Genetic manipulations of seeded endothelial cells in vascular prostheses. J Vasc Surg. 1991;13:736-738.
35. Kadletz M, Magometschnigg H, Minar E, Konig G, Grabenwoger M, Grimm M, Wolner E. Implantation of in vitro endothelialized polytetrafluoroethylene grafts in human beings. J Thorac Cardiavasc Surg. 1992;104:736-742.
36. Schneider PA, Hanson SR, Price TM, Harker LA. Durability of confluent endothelial cell monolayers on small-caliber vascular prostheses in vitro. Surgery. 1988;103:456-462.
37. Herring M, Glover JL. Endothelial Seeding in Vascular Surgery. Orlando, Fla: Grune & Stratton; 1987:120-138.
38. Greisler HP, Endean ED, Klosak JJ, Ellinger J, Henderson SC, Si M, Durham SJ, Showalter DP, Levine J, Borovetz HS. Hemodynamic effects on endothelial cell monolayer detachment from vascular prostheses. Arch Surg. 1989;124:429-433.
39. Vohra R, Thomson GJ, Carr HM, Sharma H, Walker MG. The response of rapidly formed adult human endothelial-cell monolayers to shear stress of flow: a comparison of fibronectin-coated Teflon and gelatin-impregnated Dacron grafts. Surgery. 1992;111:210-220.
40. Jensen N, Lindblad B, Leide S, Bergquist D. Loss of seeded endothelial cells in vivo: a study of Dacron grafts under different flow conditions. Eur J Vasc Surg. 1994;8:690-693.
41. Ciambrone GJ, McKeown-Longo PJ. Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells. J Cell Biol. 1990;111:2183-2195.
42. Pollanen J, Hedman C, Nielsen LS, Dano K, Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol. 1988;106:87-95.
43. Dichek DA, Anderson J, Kelly AB, Hanson SR, Harker LA. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation. 1996;93:301-309.
44. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 1981;41:4629-4636.
45. Vartio T, Seppa H, Vaheri A. Susceptibility of soluble and matrix fibronectins to degradation by tissue proteinases, mast cell chymase and cathepsin G. J Biol Chem. 1981;256:471-477.
46. Salonen E, Zitting A, Vaheri A. Laminin interacts with plasminogen and its tissue-type activator. FEBS Lett. 1984;172:29-32.
47. Schaffer LW, Davidson JT, Vlasuk GP, Dunwiddie CT, Siegl PKS. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arterioscler Thromb. 1992;12: 879-885.
48. Rade JJ, Lee SW, Dichek DA. Viral vector-mediated expression of biologically active hirudin in cultured endothelial cells. Circulation. 1993;88(suppl I):I-418. Abstract.
49. Lee SW, Kahn ML, Dichek DA. Expression of an anchored urokinase in the apical endothelial cell membrane. J Biol Chem. 1992;267:13020-13027.
50. Conte MS, Birinyi LK, Miyata T, Fallon JT, Gold HK, Whittemore AD, Mulligan RC. Efficient repopulation of denuded rabbit arteries with autologous genetically modified endothelial cells. Circulation. 1994;89:2161-2169.
51. Schwartz SM. Dynamic maintenance of the endothelium. In: Thilo-Korner DGS, Freshney RI, eds. The Endothelial Cell: A Pluripotent Control Cell of the Vessel Wall. Basel, Switzerland: Karger; 1983: 113-125.
52. Palmer TD, Rosman GJ, Osborne WRA, Miller AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci U S A. 1991;88:1330-1334.